| ￥4000 | |
| Z05143-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
>?95%?as?determined?by?Bis?Tris?PAGE? >?95%?as?determined?by?HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized CDCP1 hFc Chimera, Human at 2μg/ml (100μl/Well) on the plate can bind Biotinylated Anti?CDCP1 Antibody, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 98.4 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 115-130 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Tumor metastasis depends on the dynamic regulation of cell adhesion through β1-integrin. The Cub-Domain Containing Protein-1, CDCP1, is a transmembrane glycoprotein which regulates cell adhesion. Overexpression and loss of CDCP1 have been observed in the same cancer types to promote metastatic progression. |
| Synonyms | CDCP1; CD318; SIMA135; TRASK; UNQ2486; PRO5773 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
